Selective endothelin a receptor antagonists. 3. Discovery and structure- activity relationships of a series of 4-phenoxybutanoic acid derivatives

Journal of Medicinal Chemistry

Volumn 41, Issue 15, 1998, Pages 2732-2744

  Astles, Peter C ^a   Brealey, Clive ^a   Brown, Thomas J ^a   Facchini, Vincenzo ^a   Handscombe, Caroline ^a   Harris, Neil V ^a   McCarthy, Clive ^a   McLay, Iain M ^a   Porter, Barry ^a   Roach, Alan G ^a   Sargent, Carol ^a   Smith, Christopher ^a   Walsh, Roger J A ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 [2 CYANO 5 (3 PYRIDYLMETHOXY)PHENOXY] 4 (2 METHYLPHENYL)BUTANOIC ACID; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; RPR 111844; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; AORTA; CELL LINE; CEREBELLUM; DECEREBRATE STATE; INJECTIONS, INTRAVENOUS; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUSCLE, SMOOTH, VASCULAR; PHENYLBUTYRATES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTION;

EID: 15144345928     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9707131     Document Type: Article

References (37)

1. Yanagisawa, M.; Kurihawa, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A Novel Potent Vasoconstrictor Peptide Produced by Vascular Endothelial Cells. Nature 1988, 332, 411-415.
2. Rubanyi, G. M.; Polokoff, M. A. Endothelins: Molecular Biology, Biochemistry, Pharmacology, and Pathophysiology. Pharmacol. Rev. 1994, 46, 325-415.
3. Battistini, B.; Chailler, P.; D'Orleans-Juste, P.; Briere, N.; Sirois, P. Growth Regulatory Properties of Endothelins. Peptides 1993, 14, 385-389. Ohlstein, F. H.; Arleth, A.; Bryan, H.; Elliott, J. D.; Sung, C. P. The Selective Endothelin-A Receptor Antagonist BQ 123 Antagonizes ET-1 Mediated Mitogenesis in Vascular Smooth Muscle. Eur. J. Pharmacol. 1992, 225, 347-350.
4. Battistini, B.; Chailler, P.; D'Orleans-Juste, P.; Briere, N.; Sirois, P. Growth Regulatory Properties of Endothelins. Peptides 1993, 14, 385-389. Ohlstein, F. H.; Arleth, A.; Bryan, H.; Elliott, J. D.; Sung, C. P. The Selective Endothelin-A Receptor Antagonist BQ 123 Antagonizes ET-1 Mediated Mitogenesis in Vascular Smooth Muscle. Eur. J. Pharmacol. 1992, 225, 347-350.
5. Takayanagi, R.; Kitazumi, K.; Takasaki, C.; Ohnaka, K.; Aimoto, S.; Tasaka, K.; Ohashi, M.; Nawata, H. Presence of Non-Selective Type of Endothelin Receptor on Vascular Endothelium and its Linkage to Vasodilation. FEBS Lett. 1991, 282, 103-106.
6. B Receptors Coexist on Rabbit Pulmonary Artery Vascular Smooth Muscle Mediating Contraction. Biochem. Biophys. Res. Commun. 1993, 196, 209-215.
7. Cheng, X. M.; Doherty, A. M. Development of Agents to Modulate the Effects of Endothelin. Curr. Med. Chem. 1994, 1, 271-312.
8. A Selectivity. Potency and Solubility Enhancing Modifications. J. Med. Chem. 1992, 35, 2139-2142.
9. A Receptor Antagonist. J. Pharmacol. Exp. Ther. 1993, 264, 3301-3303.
10. B-Receptor Antagonist, BQ-788. Proc. Natl. Acad. Sci. U.S.A. 1994, 97, 4892-4896.
11. Doherty, A. M.; Cody, W. L.; DePue, P. L.; He, J. X.; Waite, L. A.; Leonard, D. M.; Leitz, N. L.; Dudley, D. T.; Rapundalo, S. T.; Hingorani, G. P.; Haleen, S. J.; LaDoudeur, D. M.; Hill, K. E.; Flynn, M. A.; Reynolds, E. E. Structure-Activity Relationships of C-Terminal Endothelin Hexapeptide Antagonists. J. Med. Chem. 1993, 36, 2585-2594.
12. Roux, S. P.; Clozel, M.; Sprecher, U.; Gray, G.; Clozel, J. P. Ro 47-0203, a New Endothelin Receptor Antagonist, Reverses Chronic Vasospasm in Experimental Subarachnoid Hemorrhage. Circulation 1993, 4 (Part 2, Suppl.), I-170.
13. Elliot, J. D.; Lago, M. A.; Cousins, R. D.; Gao, A.; Lober, J. D.; Erhard, K. F.; Nambi, P.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Bean, J. W.; DeBrosse, C. W.; Eggleston, D. S.; Brooke, D. P.; Feuerstein, G.; Ruffulo, R. R.; Weinstock, J.; Gleason, J. G.; Poishoff, C. E.; Ohlstein, E. H. 1,3-Diarylindan-2-carboxylic Acids, Potent and Selective Non-Peptide Endothelin Receptor Antagonists. J. Med. Chem. 1994, 37, 1553-1557.
14. A) Receptor-Selective Antagonists. J. Med. Chem. 1995, 38, 1259-1263.
15. A Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722. J. Med. Chem. 1996, 39, 1039-1048.
16. Astles, P. C.; Brown, T. J.; Handscombe, C. M.; Harper, M. F.; Harris, N. V.; Lewis, R. A.; Lockey, P. M.; McCarthy, C.; McLay, I. M.; Porter, B.; Roach, A. G.; Smith, C.; Walsh, R. J. A. Selective Endothelin A Receptor Antagonists. 1. Discovery and Structure Activity of 2,4-Disubstituted Benzoic Acid Derivatives. Eur. J. Med. Chem. 1997, 32, 409-423.
17. Astles, P. C.; Brown, T. J.; Harper, M. F.; Harris, N. V.; McCarthy, C.; Porter, B.; Smith, C.; Walsh, R. J. A. Selective Endothelin A Receptor Antagonists. 2. Discovery and Structure Activity of 5-Ketopentanoic Acid Derivatives. Eur. J. Med. Chem. 1997, 32, 515-522.
18. A Receptors in Humans? Trends Pharmacol. Sci. 1994, 75, 9-11. Godfraind, T. Endothelin Receptors in Human Coronary Arteries. Trends Pharmacol. Sci. 1994, 15, 136. Davenport, A. P.; Maquire, J. J. Davenport and Maquire Reply. Trends Pharmacol. Sci. 1994, 15, 136-137.
19. A Receptors in Humans? Trends Pharmacol. Sci. 1994, 75, 9-11. Godfraind, T. Endothelin Receptors in Human Coronary Arteries. Trends Pharmacol. Sci. 1994, 15, 136. Davenport, A. P.; Maquire, J. J. Davenport and Maquire Reply. Trends Pharmacol. Sci. 1994, 15, 136-137.
20. A Receptors in Humans? Trends Pharmacol. Sci. 1994, 75, 9-11. Godfraind, T. Endothelin Receptors in Human Coronary Arteries. Trends Pharmacol. Sci. 1994, 15, 136. Davenport, A. P.; Maquire, J. J. Davenport and Maquire Reply. Trends Pharmacol. Sci. 1994, 15, 136-137.
21. Maquire, J. J.; Kuc, R. E.; O'Reilly, G.; Davenport, A. P. Characterisation of Vasoconstrictor Endothelin Receptors in Human Isolated Renal Artery and Vein. Br. J. Pharmacol. 1994, 112 (Proceeding Suppl.), 495P. Maquire, J. J.; Kuc, R. E.; O'Reilly, G.; Davenport, A. P. Potency of the Novel Orally Active Endothelin Antagonist Ro 46-2005 for Endothelin Receptors in Human Vascular Smooth Muscle. Br. J. Pharmacol. 1994, 112 (Proceeding Suppl.), 552P.
22. Maquire, J. J.; Kuc, R. E.; O'Reilly, G.; Davenport, A. P. Characterisation of Vasoconstrictor Endothelin Receptors in Human Isolated Renal Artery and Vein. Br. J. Pharmacol. 1994, 112 (Proceeding Suppl.), 495P. Maquire, J. J.; Kuc, R. E.; O'Reilly, G.; Davenport, A. P. Potency of the Novel Orally Active Endothelin Antagonist Ro 46-2005 for Endothelin Receptors in Human Vascular Smooth Muscle. Br. J. Pharmacol. 1994, 112 (Proceeding Suppl.), 552P.
23. B Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation 1995, 92, 357-363. Takase, H.; Moreau, P.; Lüscher, T. F. Endothelin Receptor Subtypes in Small Arteries. Hypertension 1995, 25, 739-743.
24. B Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation 1995, 92, 357-363. Takase, H.; Moreau, P.; Lüscher, T. F. Endothelin Receptor Subtypes in Small Arteries. Hypertension 1995, 25, 739-743.
25. Hirata, Y.; Emori, T.; Eguchi, S.; Kanno, K.; Imai, T.; Ohta, K.; Marumo, F. Endothelin Receptor Subtype B Mediates Synthesis of Nitric Oxide by Cultured Bovine Endothelial Cells. J. Clin. Invest. 1993, 91, 1367-1373. Filep, J.; Battistini, B.; Coté, Y. P.; Beaudoin, A. R.; Sirois, P. Endothelin-1 Induced Prostacyclin Release From Bovine Aortic Endothelial Cells. Biochem. Biophys. Res. Commun. 1991, 177, 171-176.
26. Hirata, Y.; Emori, T.; Eguchi, S.; Kanno, K.; Imai, T.; Ohta, K.; Marumo, F. Endothelin Receptor Subtype B Mediates Synthesis of Nitric Oxide by Cultured Bovine Endothelial Cells. J. Clin. Invest. 1993, 91, 1367-1373. Filep, J.; Battistini, B.; Coté, Y. P.; Beaudoin, A. R.; Sirois, P. Endothelin-1 Induced Prostacyclin Release From Bovine Aortic Endothelial Cells. Biochem. Biophys. Res. Commun. 1991, 177, 171-176.
27. B Receptors in Rats. Biochem. Biophys. Res. Commun. 1994, 199, 1461-1465.
28. Loffler, B. M.; Breu, V.; Clozel, M. FEBS Lett. 1993, 333, 108-110.
29. Ashton, M. J.; Jaye, M. C.; Mason, J. S. New Perspectives in Lead Generation II: Evaluating Molecular Diversity. Drug Discovery Today 1996, 1, 71-78.
30. Fujimoto, M.; Mihara, S.; Nakajima, S.; Ueda, M.; Nakamura, M.; Sakurai, K. A Novel Non-Peptide Endothelin Antagonist Isolated From Bayberry, Myrica cerifia. FEBS Lett. 1992, 304, 41-44.
31. Nakamura, E.; Oshino, H.; Kuwajima, I. Trichlorotitanium and Alkoxytitanium Homoenolates. Preparation, Characterization, and Utilization for Organic Synthesis. J. Am. Chem. Soc. 1986, 108 (8), 2745-2755.
32. Singh, V. K. Practical and Useful Methods for the Enantioselective Reduction of Unsymmetrical Ketones. Synthesis 1992, 605-617.
33. Srebnick, M.; Ramachandran, P. V.; Brown, H. C. Chiral Synthesis via Organoboranes. 18. Selective Reductions. 43. Diisopinocampheylborane as an Excellent Chiral Reducing Reagent for the Synthesis of Halo Alcohols of High Enantiomeric Purity. A Highly Enantioselective Synthesis of Both Optical Isomers of Tomoxetine, Fluoxetine, and Nisoxetine. J. Org. Chem. 1988, 53, 2916-2920.
34. Astles, P. C.; Harper, M. F.; Harris, N. V.; McLay, I. M.; Walsh, R. J. A.; Lewis, R. A.; Smith, C.; Porter, B.; McCarthy, C. Preparation of Substituted Benzene Derivative Endothelin Inhibitors. WO 9513262-A, 1994.
35. Clozel, M.; Breu, V.; Burri, K.; Cassai, J.-M.; Fischli, W.; Gray, G. A.; Hirth, G.; Loffler, B.-M.; Muller, M.; Neidhart, W.; Ramuz, H. Pathophysiological Role of Endothelin Revealed By the First Orally Active Endothelin Receptor Antagonist. Nature 1993, 365, 759-761.
36. Sargent, C. A.; Brazdil, R.; Flynn, D. A.; Brown, T. J.; Roach, A. G. Effect of Endothelin Antagonists With or Without BQ 788 on ET-1 Responses in the Pithed Rat. J. Cardiovasc. Pharmacol. 1995, 26 (Suppl 3), S216-S218.
37. Mihara, S.; Nakajima, S.; Matumura, S.; Kohnoike, T.; Fujimoto, M. Pharmacological Characterisation of a Potent Nonpeptide Endothelin Receptor Antagonist, 97-139. J. Pharmacol. Exp. Ther. 1994, 265, 1122-1128.